KR20080114286A - A novel process for preparing red ginseng and the composition comprising the same - Google Patents
A novel process for preparing red ginseng and the composition comprising the same Download PDFInfo
- Publication number
- KR20080114286A KR20080114286A KR1020070063685A KR20070063685A KR20080114286A KR 20080114286 A KR20080114286 A KR 20080114286A KR 1020070063685 A KR1020070063685 A KR 1020070063685A KR 20070063685 A KR20070063685 A KR 20070063685A KR 20080114286 A KR20080114286 A KR 20080114286A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- red ginseng
- panax
- drying
- steaming
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 99
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 31
- 235000008434 ginseng Nutrition 0.000 claims abstract description 55
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 49
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 26
- 229930182490 saponin Natural products 0.000 claims abstract description 17
- 150000007949 saponins Chemical class 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 15
- 238000010025 steaming Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 7
- 240000004371 Panax ginseng Species 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 38
- 235000017709 saponins Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000013361 beverage Nutrition 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 240000005373 Panax quinquefolius Species 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 238000004904 shortening Methods 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000002791 Panax Nutrition 0.000 claims description 3
- 241000208343 Panax Species 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 241000168720 Panax japonicus Species 0.000 claims description 2
- 235000003174 Panax japonicus Nutrition 0.000 claims description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 2
- 241001527087 Panax vietnamensis Species 0.000 claims description 2
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 12
- 241000208340 Araliaceae Species 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000002000 scavenging effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- -1 peroxide nitrate Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940097156 peroxyl Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 비교실시예 1의 RGS의 퍼옥실라디칼에 대한 소거능을 나타낸 도이고, 1 is a diagram showing the scavenging ability of the RGS of Comparative Example 1 to the peroxyl radical,
도 2는 실시예 2의 NRGS의 퍼옥실라디칼에 대한 소거능을 나타낸 도이며, 2 is a diagram showing the scavenging ability of the NRGS of Example 2 for the peroxyl radical,
도 3은 비교실시예 1의 RGS의 과산화질산염에 대한 소거능을 나타낸 도이고, 3 is a diagram showing the scavenging ability of the peroxide nitrate of RGS of Comparative Example 1,
도 4는 실시예 2의 NRGS의 과산화질산염에 대한 소거능을 나타낸 도이다. 4 is a diagram showing the scavenging ability of the NRGS of Example 2 with respect to the peroxide nitrate.
본 발명의 목적은 기존의 홍삼 제조방법에 비하여 시간 단축 효과가 탁월하며 대량생산이 가능하고, 홍삼에 특이적으로 미량 존재하는 사포닌 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유할 뿐만 아니라 뛰어난 항산화 효과를 나타내는 장점을 갖는 신규한 홍삼의 제조방법 및 이를 포함하는 조성물을 제공하는 것이다. The object of the present invention is superior to the conventional method for producing red ginseng, it is excellent in reducing the time and can be mass-produced, and contains not only a large amount of saponin Rg3, Rg5, Rk1, Rh1 and Rh2 which are present in specific amounts in red ginseng as well as excellent antioxidant. It is to provide a method for producing a novel red ginseng having an advantage that shows the effect and a composition comprising the same.
35억 달러 세계 인삼시장을 잡기 위하여 국내 바이오 벤처기업들이 연간 35억 달러에 달하는 세계 인삼 관련 신 물질 개발에 열을 올리고 있다. 지금까지 인삼을 기능성식품으로 표준화해 세계 시장에서 성과를 올리고 있는 기업은 스위스 베링거잉겔하임 산하의 “파머톤사" 뿐이며 국내에서도 인삼에 대한 국가차원의 연구와 벤처업계의 상품화가 속속 진행되고 있다. To capture the $ 3.5 billion global ginseng market, Korean bio venture companies are working hard to develop new global ginseng-related materials worth $ 3.5 billion annually. Until now, the only company that has standardized ginseng as a functional food and has been performing in the global market is the “Pharmton Company” under Beringer Ingelheim, Switzerland. National research on ginseng and commercialization of the venture industry are in progress.
우리나라의 홍삼은 약 1,000년 전부터 제조된 역사적 기록을 가지고 있으며(중국 송나라의 서긍이 저술한 고려도경에 홍삼에 대한 기록이 있음), 한의학적 전통제약기술인 수치법에 의해 가공제조된 수치생약이라 할 수 있다. 일반적으로 생약의 수치목적은 1) 독성 등 부작용의 경감, 2) 생약 성능의 개변과 약효의 증강, 3) 보관이나 저장성의 향상, 4) 맛과 냄새 교정 및 부색 등으로 알려지고 있다. 일반적으로 홍삼은 적정한 열처리 공정을 거치는 동안 2차적 성분변환이 일어나 수삼(fresh ginseng)이나 백삼에 존재하지 않는 홍삼 특유의 새로운 약효성분들이 생성되기도 하고, 어떤 활성성분은 함량 증가가 일어난다. 이렇듯 인삼의 가공방법에 따라 인삼에 존재하지 않는 새로운 성분이 생성되며 인삼에 비해서 항암작용을 비롯한 여러 가지 생리활성에 대해서 보다 우수한 효과를 나타내는 새로운 가공 인삼을 개발 할 수 있다(Okamura N. et al., Biol . Pharm . Bull ., 17(2), p.270, 1994). Korean red ginseng has a historical record of about 1,000 years ago (there is a record of red ginseng in Goryeo-do, written by the Chinese Song Dynasty). have. In general, the numerical objectives of herbal medicines are known as: 1) reducing side effects such as toxicity, 2) altering herbal properties and enhancing drug efficacy, 3) improving storage and storage, and 4) correcting taste and odor and color. In general, red ginseng undergoes a second ingredient conversion during an appropriate heat treatment process, thereby generating new active ingredients unique to red ginseng or fresh ginseng, and some active ingredients increase in content. As such, new ingredients that do not exist in ginseng are produced according to the processing method of ginseng, and new processed ginsengs having better effects on various physiological activities including anticancer activity can be developed compared to ginseng (Okamura N. et al. , Biol . Pharm . Bull . , 17 (2) , p.270, 1994).
그러나 이러한 홍삼의 제조방법은 국내 공개특허공개번호 특1995-024707호(1995.09.15)에서와 같이 세척된 수삼을 세척한 후 증숙기에 넣어 94-100℃, 특히 96℃ 정도로 2-6시간정도 장시간 수증기로 증숙 하기 때문에 증숙과정 중에서 조직이 터질 염려가 있으며 인삼의 주성분인 사포닌 성분이 수분과 함께 빠져나와 사포닌의 손실이 있는 단점이 있다. However, the manufacturing method of such red ginseng is washed with fresh ginseng as in Korean Patent Application Publication No. 1995-024707 (1995.09.15) and put in a steamer at 94-100 ° C, especially 96 ° C for 2-6 hours. Because steam is steamed, tissues may burst during the steaming process, and saponin, which is the main component of ginseng, escapes with water, causing loss of saponin.
한편, 증숙에 의해서 특이적으로 많이 생성되는 Rg5는 항불안효과(Cha HY et al., Biol Pharm Bull ., 28(9), pp1621-5, 2006), 뇌기능개선효과(Kang JS et al., Arch Pharm Res ., 28(3), pp335-342, 2005), 항당뇨효과(Kordella T et al., Diabetes Forecast , 57(1), pRG5-8, 2004), C형 간염억제효과(Neuberger J et al., The Royal College of Physicians of London and the British Society of Gastroenterology., 49, Suppl 1:I1-21, 2001) 등, Rg3는 항스트레스효과(Chung BC et al., Pharmacol Res ., 54(1), pp46-9, 2006), 항암효과(Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban , 37(1), pp60-2, 2006), 간보호효과(Kim DH et al., Biol Pharm Bull ., 28(10), pp1992-4, 2005), 항산화효과(Sun YX et al., J Agric Food Chem., 51(9), pp2555-8, 2003), 신생혈관억제효과(Qui H et al., Zhonghua Wai Ke Za Zhi , 40(8), pp606-8, 2002), 혈관이완작용(Schini-Kerth VB et al., Eur J Pharmacol ., 367(1), pp51-7, 1999), 혈소판응집억제작용(Lee HK et al., Biol Pharm Bull ., 21(1), pp79-80, 1998) 등과 같은 여러 가지 생리활성을 나타낸다고 알려져 있어 이러한 사포닌이 다량 함유하는 홍삼은 위와 같은 다양한 생리활성을 기대할 수 있다.On the other hand, Rg5, which is produced specifically by steaming, has an anti-anxiety effect (Cha HY et al., Biol Pharm Bull ., 28 (9) , pp1621-5, 2006), brain function improvement effect (Kang JS et al., Arch Pharm Res . , 28 (3) , pp335-342, 2005), antidiabetic effect (Kordella T et al., Diabetes Forecast , 57 (1) , pRG5-8, 2004), hepatitis C inhibitory effect (Neuberger J et al., The royal College of Physicians of London and the British Society of Gastroenterology., 49 , Suppl 1: I1-21, 2001), etc., Rg3 has an antistress effect (Chung BC et al., Pharmacol Res . , 54 (1) , pp46-9, 2006), anticancer effect (Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban , 37 (1) , pp 60-2, 2006), hepatoprotective effect (Kim DH et al., Biol Pharm Bull ., 28 (10) , pp 1992-4, 2005), antioxidant effect (Sun YX et al., J Agric Food Chem., 51 (9) , pp2555-8, 2003), angiogenesis inhibitory effect (Qui H et al., Zhonghua Wai Ke Za Zhi , 40 (8 ), pp606-8, 2002), vasorelaxation (Schini-Kerth VB et al., Eur J Pharmacol . , 367 (1) , pp51-7, 1999), platelet aggregation inhibitory activity (Lee HK et al., Biol Pharm Bull ., 21 (1) , pp79-80, 1998), etc. It is known to exhibit various physiological activities, such that red ginseng containing a large amount of saponin can expect various physiological activities as described above.
이에 본 발명자들은 기존의 홍삼제조 방법과 비교하여 시간 단축 효과가 탁월하며 대량 생산이 가능한 표준화된 홍삼의 제조방법을 개발하였으며, 본 발명의 제조방법으로 제조된 홍삼이 기존의 방법으로 제조된 홍삼에 비해서 홍삼에 특이적 으로 미량 존재하는 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유하고, 뛰어난 항산화 효과를 나타냄을 확인함으로써 본 발명을 완성하였다. Accordingly, the present inventors have developed a standardized method of producing red ginseng, which is excellent in time reduction effect and capable of mass production, compared to the existing red ginseng manufacturing method, and the red ginseng prepared by the manufacturing method of the present invention has been prepared in the existing method. In comparison, the present invention was completed by confirming that the red ginseng contained a large amount of Rg3, Rg5, Rk1, Rh1, and Rh2, and exhibited an excellent antioxidant effect.
본 발명의 목적은 기존의 홍삼 제조 방법과 비교하여 시간 단축 효과가 탁월하며 대량 생산이 가능하고, 홍삼에 특이적으로 미량 존재하는 사포닌 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유할 뿐만 아니라 뛰어난 항산화 효과를 나타내는 장점을 갖는 신규한 홍삼의 제조방법 및 이를 함유하는 조성물을 제공하는데 있다.The object of the present invention is superior to the conventional method for producing red ginseng, it is excellent in shortening time and can be mass-produced, and contains not only a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2 which are specifically present in red ginseng, but also excellent. The present invention provides a novel method for producing red ginseng having an antioxidant effect and a composition containing the same.
상기한 목적을 달성하기 위하여, 본 발명은 인삼을 건조, 증숙 및 건조하는 공정을 통하여 시간 단축 효과가 탁월하며 대량 생산이 가능하고, 홍삼에 특이적으로 미량 존재하는 사포닌 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유할 뿐만 아니라 뛰어난 항산화 효과를 나타내는 장점을 갖는 신규한 홍삼의 제조방법을 제공한다. In order to achieve the above object, the present invention is excellent in shortening the time through the process of drying, steaming and drying ginseng and mass production is possible, specifically present in red ginseng saponin Rg3, Rg5, Rk1, Rh1 And it provides a novel method for producing red ginseng having the advantage of not only contains a large amount of Rh2 but also exhibits an excellent antioxidant effect.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 홍삼은 하기와 같이 제조될 수 있다.Red ginseng of the present invention can be prepared as follows.
본 발명의 3 내지 7년근, 바람직하게는 5년근 인삼을 세척한 후, 20 내지 60℃, 바람직하게는 35 내지 55℃의 온도에서 12 내지 36시간, 바람직하게는 20 내지 28시간 건조하는 1차 건조공정; 증숙기에 넣어 예열시간을 제외하고 0.05 내지 0.45MPa, 바람직하게는 0.10 내지 0.20MPa, 보다 바람직하게는 0.10 내지 0.14MPa의 압력하에 95 내지 155℃, 바람직하게는 110 내지 145℃, 보다 바람직하게는 116 내지 120℃의 온도에서 3 내지 30분, 바람직하게는 5 내지 15분, 보다 바람직하게는 8 내지 12분 동안 증숙하는 1차 증숙공정; 20 내지 60℃, 바람직하게는 35 내지 55℃의 온도에서 8 내지 16시간, 바람직하게는 10 내지 14시간 동안 수분함량이 14% 이하가 되도록 건조하는 2차 건조공정을 포함함을 특징으로 하는 시간 단축 효과가 탁월하며 대량 생산이 가능하고, 홍삼에 특이적으로 미량 존재하는 사포닌 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유할 뿐만 아니라 뛰어난 항산화 효과를 나타내는 장점을 갖는 홍삼의 제조 방법을 제공한다. After washing the ginseng 3 to 7 years, preferably 5 years old ginseng of the present invention, the first to dry 12 to 36 hours, preferably 20 to 28 hours at a temperature of 20 to 60 ℃, preferably 35 to 55 ℃ Drying process; 95 to 155 ° C, preferably 110 to 145 ° C, more preferably 116 under a pressure of 0.05 to 0.45 MPa, preferably 0.10 to 0.20 MPa, more preferably 0.10 to 0.14 MPa, except for the preheating time in a steamer A primary steaming step of steaming at a temperature of from 120 ° C. for 3 to 30 minutes, preferably 5 to 15 minutes, more preferably 8 to 12 minutes; A time period characterized in that it comprises a secondary drying step of drying at a temperature of 20 to 60 ° C., preferably 35 to 55 ° C., for 8 to 16 hours, preferably 10 to 14 hours, so that the moisture content is 14% or less Provides a method for producing red ginseng with excellent shortening effect and mass production, and containing a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2, which are specifically present in red ginseng, as well as showing excellent antioxidant effects. .
상기 홍삼 제조 공정에 사용되는 인삼은 고려인삼(Korea ginseng ; Panax ginseng C.A. Meyer), 화기삼(American ginseng ; Panax quinquefolium L.), 삼칠인삼(Sanchi ginseng ; Panax notoginseng ( Burk .) F. H. Chen), 죽절인삼(Chikusetsu ginseng; Panax Japonicus C. A. Meyer), 히말라야인삼(Himalayan ginsneng ; Panax pseudo-ginseng Wall . subs . himalaicus Hara) 또는 베트남인삼(Vietnamese ginseng; Panax vietnamesis Ha et Grushy), 바람직하게는 고려인삼(Korea ginseng ; Panax ginseng C.A. Meyer) 또는 화기삼(American ginseng ; Panax quinquefolium L.)임을 특징으로 한다.The ginseng used in the red ginseng manufacturing process is Korean ginseng ( Korea ginseng ; Panax ginseng CA Meyer , American ginseng ; Panax quinquefolium L. ), Sanchi ginseng ( Sanchi ginseng ; Panax notoginseng ( Burk .) FH Chen , Chikusetsu ginseng; Panax Japonicus CA Meyer ), Himalayan ginsneng ; Panax pseudo-ginseng Wall . subs . himalaicus Hara or Vietnamese ginseng; Panax vietnamesis Ha et Grushy ), preferably Korean ginseng ( Korea ginseng ; Panax ginseng CA Meyer or American ginseng ; Panax quinquefolium L. ) is characterized in that.
상기 제조 방법에 의해 제조된 홍삼은 음건, 냉동건조 등의 당업계의 통상적인 건조방법을 통하여 건조한 후, 미세입자, 바람직하게는 약 50㎛ 내지 200㎛의 입자크기로 분쇄, 분말화하는 공정을 통하여 당업계에 잘 알려진 부형제 또는 담체 를 이용하여 환제, 캅셀제, 정제 등의 조성물로 제조할 수 있다.The red ginseng prepared by the above manufacturing method is dried through a common drying method such as shade drying or freeze drying, and then pulverized and powdered into fine particles, preferably a particle size of about 50 μm to 200 μm. It can be prepared in a composition such as pills, capsules, tablets using an excipient or carrier well known in the art.
상기 방법에 의해 제조된 홍삼은 생약 분쇄기를 이용하여 미세분말, 바람직하게는 약 50~200㎛ 크기의 분말로 분쇄하여 각종제제의 원료로 사용할 수 있다.Red ginseng prepared by the above method may be used as a raw material of various preparations by grinding into fine powder, preferably a powder of about 50 ~ 200㎛ size using a herbal medicine grinder.
또한 상기 방법으로 제조된 홍삼의 추출물을 수득하는 방법을 자세히 설명하면, 상기 제조 방법으로 제조된 홍삼을 분쇄한 후, 홍삼의 약 3 내지 7배, 바람직하게는 약 4 내지 6배 질량의 물을 가하여, 실온에서 약 3 내지 7시간 방치한 후, 에탄을 0.5 내지 2ℓ를 가하여, 약 1 내지 6시간 씩, 바람직하게는 약 2 내지 4시간 씩 약 1 내지 6회, 바람직하게는 약 2 내지 4회 열수 추출, 냉침 추출, 환류 추출 또는 초음파 추출, 바람직하게는 환류 추출하고, 추출한 용액을 실온까지 냉각시킨 후 여과한 뒤 감압농축기를 이용하여 에탄올을 제거하여 본 발명의 제조방법으로 제조된 홍삼의 추출물을 수득할 수 있다.In addition, the method for obtaining the extract of the red ginseng prepared by the above method will be described in detail. After grinding the red ginseng prepared by the above method, water of about 3 to 7 times the mass of the red ginseng, preferably about 4 to 6 times the mass After the addition, the mixture was allowed to stand at room temperature for about 3 to 7 hours, and then 0.5 to 2 liters of ethane was added, about 1 to 6 hours, preferably about 2 to 4 hours, about 1 to 6 times, preferably about 2 to 4 hours Extraction of red ginseng extract, cold needle extraction, reflux extraction or ultrasonic extraction, preferably reflux extraction, cooling the extracted solution to room temperature, filtering and removing ethanol using a reduced pressure concentrator of the red ginseng prepared by the method of the present invention Extracts can be obtained.
본 발명의 제조방법은 인삼 자체뿐만 아니라 인삼잎에도 적용될 수 있다. 인삼잎은 지금까지 약용으로 사용하지는 않고 그냥 버리거나 사료용으로 사용되었으며 일부가 향장품 또는 식품의 원료로 사용되어 왔을 뿐이나, 인삼잎 추출물을 본 발명에서와 같은 방법으로 가열, 가압처리 할 경우 약효가 훨씬 강화되므로 이제까지의 인삼잎의 용도에는 물론이고 본 발명의 제조방법을 통하여 약용으로도 사용될 수 있다. The production method of the present invention can be applied to ginseng leaves as well as ginseng itself. Although ginseng leaves have not been used for medicinal purposes, they have been discarded or used for feed, and some of them have been used as raw materials for cosmetics or foods. However, when ginseng leaf extracts are heated and pressurized in the same way as in the present invention, the medicinal effect is much better. Since it is fortified, it can be used for medicinal purposes through the preparation method of the present invention as well as for the use of ginseng leaves.
상기 방법으로 제조된 홍삼은 기존의 수삼이나 백삼, 또는 기존의 홍삼에 극미량으로 존재하던 활성 성분의 함량을 증강시킴을 특징으로 한다. Red ginseng prepared by the above method is characterized in that it enhances the content of the active ingredients that were present in trace amounts of existing ginseng or white ginseng, or conventional red ginseng.
본 발명의 제조방법으로 제조된 홍삼의 추출물은 뛰어난 항산화 활성을 나 타냄을 특징으로 한다. Red ginseng extract prepared by the production method of the present invention is characterized by exhibiting excellent antioxidant activity.
본 발명은 상기 제조방법 및 추출방법으로부터 제조되는 홍삼 또는 이의 추출물을 유효성분으로 함유하는 산화관련 질환의 예방 및 치료용 약학조성물을 제공한다. The present invention provides a pharmaceutical composition for the prevention and treatment of oxidation-related diseases containing red ginseng or its extract as an active ingredient prepared from the production method and extraction method.
본 발명의 산화관련 질환의 예방 및 치료용 약학조성물은, 조성물 총 중량에 대하여 상기 홍삼 또는 추출물을 0.1 내지 50 중량%로 포함한다. The pharmaceutical composition for preventing and treating oxidation-related diseases of the present invention comprises 0.1 to 50% by weight of the red ginseng or extract based on the total weight of the composition.
본원에서 정의되는 산화관련 질환은 비만증, 노화, 당뇨병, 동맥경화증, 고지혈증, 신장질환, 통풍, 고혈압, 간질환, 폐질환, 갑상선 기능항진증, 갑상선 기능저하증, 만성피로증후군, 심장병, 중풍 또는 신경퇴행성 질환, 바람직하게는 비만증, 노화, 당뇨병, 동맥경화증, 고지혈증, 신장질환 또는 통풍을 포함한다. Oxidation-related diseases as defined herein include obesity, aging, diabetes, arteriosclerosis, hyperlipidemia, kidney disease, gout, hypertension, liver disease, lung disease, hyperthyroidism, hypothyroidism, chronic fatigue syndrome, heart disease, stroke or neurodegenerative disease Diseases, preferably obesity, aging, diabetes, arteriosclerosis, hyperlipidemia, kidney disease or gout.
본 발명의 홍삼 또는 이의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. The pharmaceutical composition comprising red ginseng of the present invention or extract thereof may further include appropriate carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명의 홍삼 및 이의 추출물의 약학적 투여 형태는 이들의 약학적 허용가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage forms of the red ginseng and extracts thereof of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.
본 발명에 따른 홍삼 또는 이의 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락 토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전 Pharmaceutical compositions comprising red ginseng or extracts thereof according to the present invention, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Formulated in the form of can be used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, total
분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Powder, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and Mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 홍삼 및 이의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하 게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.2 내지 200㎎/kg으로, 바람직하게는 2 내지 100㎎/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. Preferred dosages of the red ginseng of the present invention and extracts thereof vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.2 to 200 mg / kg, preferably 2 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 홍삼 및 이의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. The red ginseng of the present invention and extracts thereof may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명의 제조방법으로 제조된 홍삼 및 이의 추출물은 기존의 인삼이 사용되어오던 용도, 즉 각종 의약품 제제, 한약, 건강식품, 식품, 차, 향장품 등에 원래 인삼보다 더 효능이 강화된 원료로 사용될 수 있다. Red ginseng and its extract prepared by the method of the present invention can be used as a raw material that is more potent than the original ginseng, that is, conventional ginseng has been used, that is, various pharmaceutical preparations, Chinese medicine, health food, food, tea, cosmetics, etc. have.
본 발명의 홍삼 및 이의 추출물은 독성 및 부작용은 거의 없으므로 예방 또는 치료의 목적으로 장기간 복용시에도 안심하고 사용할 수 있다. Red ginseng of the present invention and extracts thereof have little toxicity and side effects, so can be used safely even for long-term administration for the purpose of prevention or treatment.
본 발명은 상기 제조방법 및 추출방법으로부터 제조되는 홍삼 또는 이의 추출물을 유효성분으로 함유하는 산화관련 질환의 예방 및 개선용 건강기능식품을 제공한다. The present invention provides a health functional food for the prevention and improvement of oxidation-related diseases containing red ginseng or its extract as an active ingredient prepared from the production method and the extraction method.
상기 홍삼 및 이의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류, 분말, 과립, 정제, 캡슐 또는 음료 등이 있다. The food to which the red ginseng and its extract may be added include, for example, various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules or beverages.
또한, 산화관련 질환의 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 흑삼 및 이의 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다. It may also be added to food or beverages for the purpose of preventing oxidation-related diseases. At this time, the amount of the black ginseng and its extract in the food or beverage may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 5g, preferably 0.3 to 1g based on 100ml Can be added.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 홍삼 또는 화기홍삼 및 이의 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다. The health functional beverage composition of the present invention is not particularly limited to other ingredients other than containing the red ginseng or red ginseng and extract thereof as essential ingredients in the indicated ratios, and additional ingredients such as various flavors or natural carbohydrates, such as ordinary drinks. It may contain as. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 홍삼 및 이의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물들은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립 적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다. In addition to the red ginseng of the present invention and extracts thereof, various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다. Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실험예에 의해 한정되는 것은 아니다. However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Experimental Examples.
비교실시예Comparative Example 1. 정관장 홍삼 추출물의 제조 1. Preparation of Jeonggwanjang Red Ginseng Extract
정관장 홍삼 32.75g을 분쇄한 후 80%에탄올 1L를 넣고 4시간씩 3회 환류 추출한 다음, 추출한 용액을 실온까지 냉각시킨 후 여과한뒤, 감압 농축기로 용매를 제거하여 홍삼 조추출물 9g을 수득하였고, 이 홍삼 조추출물에 물 300㎖를 넣어 현탁시킨 후 에테르 300㎖를 가하여 비극성 물질을 제거하였으며, 남아있는 수층에 수포화 부탄올 300㎖를 가하여 인삼에 존재하는 사포닌을 추출한 후 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 홍삼 추출물 1.25g을 얻었고(이하, RGS라 명명함), 하기 실험예의 시료로 사용하였다. After pulverizing 32.75 g of red ginseng jeonggwanjang, 1L of 80% ethanol was added and refluxed three times for 4 hours. The extracted solution was cooled to room temperature, filtered, and the solvent was removed using a vacuum condenser to obtain 9 g of red ginseng crude extract. 300 ml of water was added to the red ginseng crude extract and suspended. Then, 300 ml of ether was added to remove the nonpolar substance. 300 ml of saturated butanol was added to the remaining aqueous layer to extract saponin present in ginseng, and the butanol was removed using a vacuum concentrator. 1.25 g of red ginseng extract containing a large amount of ginseng saponin was obtained (hereinafter referred to as RGS), and used as a sample of the following experimental example.
실시예Example 1. 홍삼의 제조 1. Preparation of Red Ginseng
금산에서 생산되어 유통되는 6년근 고려인삼(Panax ginseng C. A. Meter) 2 kg을 구입한 후 고려인삼을 스크류 세척기에 넣고 10분간 총 3회 반복해서 세척과 정 중에 거피가 되지 않도록 주의하면서 세척하였고, 세척된 고려인삼을 40℃에서 24시간 1차 건조하였으며, 24시간 저온에서 말린 고려인삼을 증숙기에 넣고 예열시간을 제외하고 가압하에(0.12MPa) 118℃에서 10분간 증숙한 후, 건조기로 50 ℃에서 12시간 동안 2차 건조하여 수분함량이 14%인 본 발명의 홍삼 475g을 제조하였다(이하, HS라 명명함). Panax ginseng ( Panax ginseng) produced and distributed in Geumsan ginseng CA Meter ) After purchasing 2 kg, Korean ginseng was put in a screw washer and washed three times for 10 minutes, taking care not to peel off during the washing process, and the dried Korean ginseng was first dried at 40 ℃ for 24 hours. Place Korean ginseng dried at low temperature for 24 hours in a steamer, steam for 10 minutes at 118 ℃ under pressure (0.12MPa) except for preheating time, and then dry it for 2 hours at 50 ℃ for 12 hours to dry out. 475 g of red ginseng of the present invention was prepared (hereinafter referred to as HS).
실시예Example 2. 홍삼 추출물의 제조 2. Preparation of Red Ginseng Extract
실시예 1의 HS 30.44g을 취하여 분쇄한 후 80%에탄올 1L를 넣고 4시간씩 3회 환류 추출하여 추출한 용액을 실온까지 냉각시킨 후 여과한 뒤 감압농축기를 이용하여 용매를 제거하여 홍삼 조추출물 8.4g을 수득하였고, 이 홍삼 조추출물에 물 300㎖를 넣어 현탁시킨 후 에테르 300㎖를 가하여 비극성 물질을 제거하였으며, 남아있는 수층에 수포화 부탄올 300㎖를 가하여 고려인삼에 존재하는 사포닌을 추출한 후 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 홍삼 추출물 1.14g을 얻었고(이하, NRGS라 명명함), 하기 실험예의 시료로 사용하였다. Take 30.44 g of HS of Example 1, grind, add 1 L of 80% ethanol and reflux three times for 4 hours. The extracted solution was cooled to room temperature, filtered, and the solvent was removed using a vacuum condenser to extract red ginseng crude 8.4. g was obtained, and 300 ml of water was added to the crude red ginseng extract and suspended. Then, 300 ml of ether was added to remove the nonpolar substance. 300 ml of saturated butanol was added to the remaining aqueous layer to extract saponin present in Korean ginseng, and then butanol. Was removed by a vacuum condenser to obtain 1.14g of red ginseng extract containing a large amount of ginseng saponin (hereinafter referred to as NRGS), was used as a sample of the following experimental example.
실시예Example 3. 화기홍삼의 제조 3. Preparation of Hwagi Red Ginseng
상기 실시예 1에서 5년근 고려인삼 2kg을 6년근 화기삼(Panax quinquefolium L.) 50g으로 바꾸는 것만 제외하고 동일한 공정을 수행하여 본 발명의 화기홍삼 50g을 제조하였다(이하, WGHS라 명명함). 5 years old Korean ginseng 2kg 6 years old ginseng ( Panax) in Example 1 quinquefolium L. ) 50g of Hwagi red ginseng of the present invention was prepared by following the same procedure except changing to 50g (hereinafter, referred to as WGHS).
실시예Example 4. 화기홍삼 추출물의 제조 4. Preparation of Hwagi Red Ginseng Extract
상기 실시예 2에서 실시예 1의 HS 30.44g을 실시예 3의 WGHS 50g으로 바꾸는 것만 제외하고 동일한 공정을 수행하여 화기홍삼 추출물 4.82g을 얻었고(이하, WGRGS라 명명함), 하기 실험예의 시료로 사용하였다. Except for changing the HS.30.44g of Example 1 in Example 2 to 50g of WGHS in Example 3 to obtain 4.82g Hwagi red ginseng extract (hereinafter referred to as WGRGS), the sample of the following Experimental Example Used.
실험예Experimental Example 1. 홍삼 사포닌 성분 분석 1. Red Ginseng Saponin Analysis
홍삼 추출물에 존재하는 인삼사포닌의 성분을 분석하기 위하여 비교실시예 1의 RGS, 실시예 2의 NRGS 또는 실시예 4의 WGRGS 20㎎을 메탄올 1㎖에 녹인 후 0.45㎛ 필터로 여과한 여액을 하기 표 1의 HPLC 분석 조건으로 성분을 분석하였고, 그 결과를 하기 표 2에 나타내었다. In order to analyze the components of ginseng saponin present in the red ginseng extract, 20 mg of RGS of Comparative Example 1, NRGS of Example 2 or WGRGS of Example 4 was dissolved in 1 ml of methanol, and the filtrate was filtered with a 0.45 μm filter. The components were analyzed by HPLC analysis conditions of 1, and the results are shown in Table 2 below.
실험 결과, 상기 표 2에 나타난 바와 같이, 실시예 2의 NRGS는 Rg3 함량이 0.102%로 비교실시예 1의 RGS의 Rg3 함량이 0.061%인 것과 비교하여 약 1.7배 증가하였다. 또한 실시예 2의 NRGS는 Rk1+Rg5의 함량이 0.128%로 비교실시예 1의 RGS의 RK1+RG5 함량이 0.053%인 것과 비교하여 함량이 2 배 이상 증가하였으며, Rh1 및 Rh2의 경우에도 실시예 2의 NRGS가 비교 실시예 1의 RGS에 비하여 함량이 약 1.7 배 증가하였음을 관찰할 수 있었다. 또한 실시예 4의 WGRGS는 Rg3 함량이 0.212%로 비교실시예 1의 RGS와 비교하여 약 3.5배 증가하였고, RK1+Rg5 함량이 0.212%로 비교실시예 1의 RGS와 비교하여 약 4배 증가하였으며, Rh1의 경우 약 1.2배, Rh2의 경우 약 3배 가량 증가하였음을 관찰할 수 있었다. As a result, as shown in Table 2, the NRGS of Example 2 was increased by about 1.7 times as compared to the Rg3 content of the RGS of Comparative Example 1 was 0.061% to 0.102% Rg3 content. In addition, the NRGS of Example 2 had an Rk1 + Rg5 content of 0.128%, which was more than two times higher than the RK1 + RG5 content of RGS of Comparative Example 1, which was 0.053%, and in the case of Rh1 and Rh2. It can be observed that the NRGS of 2 increased about 1.7 times as compared to the RGS of Comparative Example 1. In addition, the WGRGS of Example 4 was increased by about 3.5 times compared to the RGS of Comparative Example 1 with an Rg3 content of 0.212%, and increased by about 4 times compared with the RGS of Comparative Example 1 with RK1 + Rg5 content of 0.212%. , Rh1 increased about 1.2 times, and Rh2 increased about 3 times.
이로부터 본 발명의 제조방법으로 제조된 홍삼 및 이의 추출물은 기존 홍삼에 미량으로 존재하는 사포닌 Rg3, Rk1, Rg5, Rh1 및 Rh2를 다량 함유함을 알 수 있었다. From this, the red ginseng prepared by the preparation method of the present invention and its extracts were found to contain a large amount of saponins Rg3, Rk1, Rg5, Rh1 and Rh2 present in trace amounts in the existing red ginseng.
실험예 2. 옥시라디칼 소거능 측정Experimental Example 2. Oxy radical scavenging activity
실시예 2의 NRGS 또는 실시예 4의 WGRGS의 라디칼 소거능을 측정함으로써 항산화 효과를 알아보기 위해 TOSC(총 옥시라디칼 소거능) 분석법(Winston et al., Free Radic Biol Med., Feb, 24(3), pp480-493, 1998; Regoli and Winston, Toxicol Appl Pharmacol., Apr 15, 156(2), pp96-105, 1999)을 이용하여 하기와 같이 실험을 수행하였다.TOSC (Total Oxy Radical Scavenging Activity ) Assay (Winston et al., Free Radic Biol Med., Feb, 24 (3), to determine the antioxidant effect by measuring the radical scavenging ability of NRGS of Example 2 or WGRGS of Example 4 , pp480-493, 1998; Regoli and Winston, Toxicol Appl Pharmacol., Apr 15, 156 (2) , pp96-105, 1999).
20 mM 농도의 ABAP(2,2'-아조비사미디노프로판, 시그마사)를 35℃에서 자발적으로 붕괴시켜 퍼옥실 라디칼을 발생시켰고, 70 microM의 SIN-1(시그마사)을 자발적으로 붕괴시켜 과산화질산염을 발생시켰으며, 발생된 퍼옥시 라디칼 및 과산화질산염은 반응액에 0.2 mM 농도로 존재하는 KMBA(α-케토-γ-메티올부티르산, 시그마사)과 반응하여 에틸렌 가스를 발생시켰고, 비교실시예 1의 RGS, 실시예 2의 NRGS 또는 실시예 4의 WGRGS와의 반응에 따른 에틸렌 가스 검출 여부를 확인함으로써, 이들의 옥시라디칼 소거능을 측정하였다. 20 mM concentration of ABAP (2,2'-azobisamidinopropane, Sigma) spontaneously decomposed at 35 ° C. to generate peroxyl radicals and spontaneous decay of 70 microM SIN-1 (Sigma) Peroxynitrate was generated, and the peroxy radical and peroxide nitrate generated were reacted with KMBA (α-keto-γ-metholbutyric acid, Sigma) present in 0.2 mM concentration in the reaction solution to generate ethylene gas. The oxyradical scavenging ability was measured by confirming whether ethylene gas was detected by the reaction with RGS of Example 1, NRGS of Example 2 or WGRGS of Example 4.
비교실시예 1의 RGS, 실시예 2의 NRGS 또는 실시예 4의 WGRGS를 0.0125, 0.025, 0.05 또는 0.1mg/ml의 농도로 물과 희석하여 최종 용량이 1 ml가 되도록 만든 다음, 고무로 된 셉텀(rubber septum)으로 밀폐된 10ml의 용기에 넣었고, 반응용기의 헤드 스페이스 내부 공기 200 microL를 취하여 헤드-스페이스 법(head-space technique)으로 하기 표 3에 기재된 조건의 가스 크로마토그래피(GC, gas chromatography)를 수행하였고, 바이알(Vial)의 에틸렌 가스(ethylene gas) 정량을 위해 바이알 안의 공기를 가스 밀폐된(gas-tight) 주사기로 150 μl 취하여 가스 밀폐된(gas-tight) 주사기로 취하여 인젝터(injector)에 주입하였으며, 이로부터 얻은 그래프(도 1 내지 도 4 참조)로부터 하기 수학식 1을 이용하여 TOSC값을 구하였고, 그 결과를 하기 표 4 및 표 5에 나타내었다. RGS of Comparative Example 1, NRGS of Example 2 or WGRGS of Example 4 were diluted with water to a concentration of 0.0125, 0.025, 0.05 or 0.1 mg / ml to a final volume of 1 ml and then rubber septum It was placed in a sealed 10 ml vessel with a rubber septum, and 200 microL of air in the head space of the reaction vessel was taken, and the head-space technique was used for gas chromatography (GC) under the conditions shown in Table 3 below. 150 μl of air in the vial was taken with a gas-tight syringe to inject the gas-tight syringe into the injector to quantify the ethylene gas of the vial. ), The TOSC value was obtained from Equation 1 below using the graph (see FIGS. 1 to 4), and the results are shown in Tables 4 and 5 below.
∫SA = 시료 반응의 곡선으로부터 적분한 범위∫SA = range integrated from the curve of the sample response
∫CA = 대조군 반응의 곡선으로부터 적분한 범위∫CA = integrated range from curve of control response
실험결과, 상기 표 4 및 표 5에 나타난 바와 같이, 실시예 2의 NRGS는 퍼옥실 라디칼(peroxyl radicals)에 대한 특정 TOSC값이 423±4 TOSC/mg으로 비교실시예 1의 RGS가 377±14 TOSC/mg인 것과 비교하여 약 46 TOSC/mg이 더 높았고, 실시예 4의 WGRGS는 TOSC값이 390±26 TOSC/mg으로 비교실시예 1의 RGS와 비교하여 약 13 TOSC/mg이 더 높았으며, 실시예 2의 NRGS는 과산화질산염(peroxynitrite)에 대한 특정 TOSC값이 379±10 TOSC/mg으로 비교실시예 1의 RGS가 336±8 TOSC/mg인 것과 비교하여 약 43 TOSC/mg이 높았고, 실시예 4의 WGRGS는 TOSC값이 360±25로 비교실시예 1의 RGS와 비교하여 약 24 TOSC/mg이 더 높았으며, 이로부터 본 발명의 홍삼 또는 화기홍삼의 추출물은 퍼옥실 라디칼 및 과산화질산염에 대해 높은 항산화 활성을 나타내며, 기존 제조방법으로 제조된 홍삼과 비교하여 훨씬 뛰어난 항산화 활성을 나타냄을 알 수 있었다. As a result, as shown in Table 4 and Table 5, the NRGS of Example 2 has a specific TOSC value of 423 ± 4 TOSC / mg for peroxyl radicals, and the RGS of Example 1 is 377 ± 14. About 46 TOSC / mg was higher compared to TOSC / mg, WGRGS of Example 4 had a TOSC value of 390 ± 26 TOSC / mg, which was about 13 TOSC / mg higher than the RGS of Comparative Example 1 The NRGS of Example 2 had a specific TOSC value of 379 ± 10 TOSC / mg for peroxynitrite, which was about 43 TOSC / mg higher than the RGS of Comparative Example 1, which was 336 ± 8 TOSC / mg, WGRGS of Example 4 had a TOSC value of 360 ± 25, which was about 24 TOSC / mg higher than that of RGS of Comparative Example 1. From this, the extract of red ginseng or red ginseng of the present invention contained peroxyl radical and peroxide nitrate It has high antioxidant activity against, and shows much better antioxidant activity compared to red ginseng prepared by conventional manufacturing methods. I could see the smell.
실험예 3. 급성독성실험Experimental Example 3. Acute Toxicity Test
6 주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트를 사용하여 급성독성실험을 실시하였다. 각 그룹 당 2마리씩의 동물에 실시예 2의 NGRS 또는 실시예 4의 WGRGS를 1g/㎏의 용량으로 1회 경구투여 하였다. 실험 물질 투여 후 동물의 폐사여부, 임상증상 및 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 강장기와 흉강 장기의 이상여부를 관찰하였다. Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals in each group were orally administered NGRS of Example 2 or WGRGS of Example 4 at a dose of 1 g / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.
그 결과, 실험 물질을 투여한 모든 동물에서 특이할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사 및 부검 소견 등에서도 독성변화는 관찰되지 않았다. 이상의 결과, 본 발명의 추출물은 랫트에서 각각 1g/㎏까지도 독성변화를 나타내지 않았으며, 경구투여 최소치사량(LD50)은 1g/㎏이상인 안전한 물질로 판단되었다.As a result, no clinical symptoms or dead animals were observed in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. As a result, the extract of the present invention did not show a change in toxicity even in rats up to 1 g / kg, respectively, the minimum lethal dose (LD 50 ) was determined to be a safe substance of more than 1 g / kg.
하기에 상기 홍삼 또는 추출물을 포함하는 조성물의 제제예를 설명하나, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다. Hereinafter, the preparation examples of the composition comprising the red ginseng or extract, but this is not intended to limit the present invention only intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
실시예 1의 HS 20 mg
유당 100 mgLactose 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다. The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
실시예 3의 WGHS 10 mg10 mg of WGHS of Example 3
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다. After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Manufacture of capsule
실시예 2의 NRGS 10 mg10 mg of NRGS of Example 2
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다. According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
실시예 4의 WGRGS 10 mg10 mg of WGRGS of Example 4
만니톨 180 mgMannitol 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4·12H2O 26 mg Na 2 HPO 4 · 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다. According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
실시예 2의 NRGS 20 mg20 mg of NRGS of Example 2
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다. According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added to the mixture, and then the above ingredients are mixed, purified water is added to adjust the total amount to 100 ml, and then filled in a brown bottle. The solution is prepared by sterilization.
제제예Formulation example 6. 건강 식품의 제조 6. Manufacture of healthy food
실시예 1의 HS 1000 ㎎
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B 1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B 2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B 6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B 12
비타민 C 10 ㎎
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎Calcium Carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다. Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
실시예 4의 WGRGS 100 ㎎WGRGS 100 mg of Example 4
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B 1
비타민 B2 0.3g0.3 g of vitamin B 2
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components in accordance with the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
상기와 같이, 본 발명은 기존의 홍삼 제조방법과 비교하여 시간 단축 효과가 탁월하며 대량 생산이 가능하고, 홍삼에 특이적으로 미량 존재하는 사포닌 Rg3, Rg5, Rk1, Rh1 및 Rh2를 다량 함유할 뿐만 아니라 뛰어난 항산화 효과를 나타내는 장점을 갖는 신규한 홍삼의 제조방법 및 이를 함유하는 조성물을 제공한다. As described above, the present invention is superior to the conventional red ginseng manufacturing method, the time-saving effect is excellent and can be mass-produced, and contains a large amount of saponins Rg3, Rg5, Rk1, Rh1 and Rh2 which are present in specific amounts in red ginseng. As well as a novel method for producing red ginseng having the advantages of showing an excellent antioxidant effect and a composition containing the same.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070063685A KR100889950B1 (en) | 2007-06-27 | 2007-06-27 | A novel process for preparing red ginseng and the composition comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070063685A KR100889950B1 (en) | 2007-06-27 | 2007-06-27 | A novel process for preparing red ginseng and the composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080114286A true KR20080114286A (en) | 2008-12-31 |
| KR100889950B1 KR100889950B1 (en) | 2009-03-20 |
Family
ID=40371411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070063685A KR100889950B1 (en) | 2007-06-27 | 2007-06-27 | A novel process for preparing red ginseng and the composition comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100889950B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101348974B1 (en) * | 2011-12-13 | 2014-01-10 | 한국식품연구원 | Preparation method for novel red ginseng using reduced-pressure drying after high temperature high pressure process |
| KR101593436B1 (en) * | 2015-06-18 | 2016-02-12 | 박석하 | Ginseng manufacturing method using a high-temperature/high-pressure |
| CN105853451A (en) * | 2015-01-21 | 2016-08-17 | 熊慧 | Application of ginsenosideRg3, ginsenosideRg5 and/or ginsenosideRk1 in preparation of medicines or health food for treating gout |
| EP2982376A4 (en) * | 2013-04-02 | 2017-01-04 | Amorepacific Corporation | Composition for brain activation, comprising ginseng berry extract |
| KR102100453B1 (en) * | 2019-07-02 | 2020-04-14 | 주식회사 진산사이언스 | Process technology for improved bitterness, Rg5 and Rk1 enriched low temperature vacuum dryer from red ginseng concentrated extract |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101117072B1 (en) | 2009-05-19 | 2012-02-22 | 한국원자력연구원 | Preparation method of redginseng and blackginseng for increasing ginsenoside using radiation rays |
| KR101602910B1 (en) * | 2011-06-07 | 2016-03-15 | 주식회사 아리바이오 | Methods for Enrichment of Ginsenosides |
| KR101467522B1 (en) * | 2013-01-31 | 2014-12-01 | 주식회사 세바바이오텍 | Manufacturing of enhancing low molecular ginsenosides contents of ginseng by decompression recirculation high speed steaming process device |
| CN104643058A (en) * | 2013-11-21 | 2015-05-27 | 富力 | Application of 20(R)-ginsenoside Rg3 in preparation of medicines for improving or/and treating liver cirrhosis diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100531429B1 (en) * | 2003-05-31 | 2005-11-28 | 엔티앤비티(주) | Manufacturing process of Black-Red ginseng and the processed goods |
| KR100522913B1 (en) * | 2003-12-17 | 2005-10-24 | 김현순 | producing method of ginseng dried in its original shape with red cuticle |
| KR100730647B1 (en) * | 2005-06-17 | 2007-06-20 | (주)김가고려인삼 | Aged Concentrate of Ginseng Steamed Red, and a Preparation Method Thereof |
| KR100876278B1 (en) * | 2006-01-25 | 2008-12-26 | 주식회사 진산삼바이오 | Manufacturing method of red ginseng cultured ginseng cultured ginseng and method of increasing the content of red ginseng components |
-
2007
- 2007-06-27 KR KR1020070063685A patent/KR100889950B1/en not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101348974B1 (en) * | 2011-12-13 | 2014-01-10 | 한국식품연구원 | Preparation method for novel red ginseng using reduced-pressure drying after high temperature high pressure process |
| EP2982376A4 (en) * | 2013-04-02 | 2017-01-04 | Amorepacific Corporation | Composition for brain activation, comprising ginseng berry extract |
| US10555983B2 (en) | 2013-04-02 | 2020-02-11 | Amorepacific Corporation | Composition for brain activation, comprising ginseng fruit extract |
| CN105853451A (en) * | 2015-01-21 | 2016-08-17 | 熊慧 | Application of ginsenosideRg3, ginsenosideRg5 and/or ginsenosideRk1 in preparation of medicines or health food for treating gout |
| KR101593436B1 (en) * | 2015-06-18 | 2016-02-12 | 박석하 | Ginseng manufacturing method using a high-temperature/high-pressure |
| KR102100453B1 (en) * | 2019-07-02 | 2020-04-14 | 주식회사 진산사이언스 | Process technology for improved bitterness, Rg5 and Rk1 enriched low temperature vacuum dryer from red ginseng concentrated extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100889950B1 (en) | 2009-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100889950B1 (en) | A novel process for preparing red ginseng and the composition comprising the same | |
| KR101082181B1 (en) | A method for preparing novel black-red ginseng and the extract therefrom and the composition comprising the same | |
| KR102070297B1 (en) | Panax spp. plant extract with increased content ratio of ginsenoside Rg3, Rg5 and Rk1 produced by microwave irradiation, a process for the preparation thereof, and a composition comprising the same | |
| KR100754253B1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
| KR100854442B1 (en) | Composition comprising an extract of Nelumbinis Folium or herb complex for preventing or treating hyperlipidemia and arteriosclerosis | |
| KR101793503B1 (en) | Composition for prevention or treatment of neurodegenerative diseases | |
| KR100868249B1 (en) | A pharmaceutical composition and health care food comprising novel black ginseng leaf and the extract thereof showing anti-aging activity prepared by novel process | |
| KR101375483B1 (en) | Ginseng prosapogenin high concentration containing Sanchi ginseng preparation using sonication and process for thereof | |
| KR20100130020A (en) | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process | |
| KR100692402B1 (en) | A pharmaceutical composition comprising the extract of gardenia for treating or preventing depression disease | |
| KR100462788B1 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
| KR101082173B1 (en) | A method for preparation of flower bud of black ginseng and a composition comprising the extract thereof showing anti-aging activity | |
| KR100781571B1 (en) | Pharmaceutical composition comprising an extract of novel black ginseng | |
| KR100844991B1 (en) | A composition comprising the extract of black ginseng leaf showing anti-cancer activity | |
| KR101374351B1 (en) | A composition comprising the dried flower bud powder of Black Panax ginseng for treating and preventing atopic disease | |
| KR101127329B1 (en) | A composition comprising the extract prepared by novel method for preparing black-red ginseng | |
| KR101082262B1 (en) | Composition comprising an extract of black ginseng showing anti-aging activity | |
| KR20130080644A (en) | A composition comprising the extract of red ginseng for treating and preventing atopic disease | |
| KR100637263B1 (en) | A pharmaceutical composition comprising the extract of Sorbus amurensis KOEHNE for treating or preventing cerebrovascular system disease | |
| KR20130103097A (en) | Processed panax spp. plant extract with increased content ratio of ginsenoside rg5 or ginsenoside rk1, a process for the preparation thereof, and a composition comprising the same | |
| KR20080016291A (en) | A composition comprising novel black ginseng and the extract thereof for the prevention and treatment of diabetes mellitus prepared by novel process | |
| KR20130043767A (en) | A composition comprising the extract of processed panax genus plant for treating and preventing liver disease and hepato-protective activity | |
| KR100555653B1 (en) | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety | |
| KR100679319B1 (en) | A pharmaceutical composition comprising the extract of dandelion for treating or preventing depression disease | |
| KR20080056651A (en) | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120316 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |